Herpes Zoster Vaccine Gsk1437173A
Cardiovascular Disorder
Explore 55 assets in Cardiovascular Disorder →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Tor Biering-Sørensen
Modality
vaccine
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07485283CT.gov Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cardiovascular Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Herpes Zoster Vaccine Gsk1437173A (this asset) | Tor Biering-Sørensen | Approved | BB · 65 |
| Aspirin | AstraZeneca | P4 | BBB |
| Liraglutide | University of Sao Paulo General Hospital | P4 | BBB |
| Atorvastatin | Duke University | P4 | BBB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BBB |
| Simvastatin | McMaster University | P4 | BBB |
| Ramifentanyl | Helse Fonna | P4 | BBB |
| Hydrochlorothiazide | Tehran University of Medical Sciences | P4 | BBB |
| Degarelix | Rabin Medical Center | P4 | BBB |
+42 more in the Cardiovascular Disorder cohort
Other indications for Herpes Zoster Vaccine Gsk1437173A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Dementia | — | P4 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Herpes Zoster Vaccine Gsk1437173A in Cardiovascular Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/herpes-zoster-vaccine-gsk1437173a-cardiovascular-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →